|Post title||Commercial Contracts Manager|
|Budget centre||Precision Health Technologies Accelerator Ltd (a wholly-owned subsidiary of the University of Birmingham)|
|Full/part time||Full time|
|Salary||£45,000 – £65,000 depending on experience|
|Additional information||Company bonus scheme, generous holiday allowance|
|Closing date||Friday 15th October 2021|
|UoB equivalent grade||Grade 8/9|
As a key role in the commercial success of the newly-formed PHTA Ltd, the Commercial Contracts Manager will work closely with the Managing Director and leading academics within the University, to develop and secure high-value commercial contracts with a wide range of health and life sciences businesses.
Focussing initially on work generated through the Birmingham Precision Medicine Centre division of PHTA Ltd, the role-holder will be critical to helping the business grow the industry facing offering through our engagements with biotech, pharma and medical device companies to deliver new medicines and therapies.
Initially, a significant proportion of contracts being negotiated and executed will relate to novel clinical trials with the pharmaceutical industry, and BPMC will rely on the academic and clinical leadership and delivery capabilities of the University Trials Units who will be critical partners in the success and delivery of negotiated contracts. As such the post-holder will be working closely with both the Industry Trials Hub Team Lead within BPMC as well as existing trials management staff in the Cancer Research UK Clinical Trials Unit and Birmingham Clinical Trials Unit within the University. The University Trials Units maintain strong relationships with all of the major global pharmaceutical companies and it will be important for the post-holder to build on and rapidly develop and maintain professional, commercial relationships with these key industrial partners whilst not conflicting these existing academic partnerships.
The post-holder will be responsible for establishing a commercially customer-focussed, professional culture ensuring that the contracting process between industry customers, the PHTA and with the University is delivered to the highest quality in the preparation, review, negotiation and approval of a broad range of research contracts. Key will be meeting the timescales and expectations of industry customers and balancing this with the appropriate assessment of contractual risk, the timely resolution of complex contractual issues and engagement with the University Trials Units.
Alongside the contracts for the delivery of novel clinical trials, BPMC will also be involved in delivering major diagnostic programmes with industry and the NHS, some of which may be linked to novel clinical trials programmes (e.g. companion diagnostic studies).
Working with the Managing Director, the post holder will develop appropriate KPIs and be required to monitor service performance and where appropriate implement system and process improvements to respond to changing needs and circumstances and ensure that the business can deliver consistently outstanding support.
The post holder will be required to maintain a comprehensive understanding of the University’s research governance, ethics and GDPR arrangements and maintain strong working relations with the contracts and research governance professional services teams within the University. They will also be required to keep up to date of relevant changes in the Law.
As the business grows, it is expected that the postholder’s role will develop and they will be responsible for the appointment and management of additional staff looking after commercial and contract development and the concomitant responsibilities that brings including setting the strategic aims and goals of the team.
The University of Birmingham is leading transformational change in the region’s health and life sciences innovation ecosystem that will deliver significant and long-lasting improvements to the health and wealth, of the region and nationally.
Working as Birmingham Health Partners (BHP), the Midland’s leading academic-NHS partnership, the University is building on BHP’s nationally recognised strengths in healthcare data informatics and systems; genomics medicine and diagnostics; medical technologies evaluation and clinical trials, to establish the Precision Health Technologies Accelerator (PHTA) – the anchor innovation capability on the new Birmingham Health Innovation Campus due to open in 2023.
The PHTA will provide the early incubation, grow-on space and innovation services for businesses working across biopharma (including advanced therapies), diagnostics, digital health and advanced healthcare technologies to accelerate the development and delivery of new precision drugs, diagnostics and healthcare technologies into the clinic. Run and operated by PHTA Ltd, a wholly owned subsidiary company of the University of Birmingham, PHTA will deliver a commercially-focused, innovative end-to-end clinical and academic partnership for the delivery of precision medicine solutions. Ahead of the facility opening, PHTA Ltd will operate from within the Institute of Translational Medicine, building a strong pipeline of commercial projects through one of its two divisions: Birmingham Precision Medicine Centre (BPMC).